Materials and methods
Potassium tetrachloridoplatinate (K 2 PtCl 4 ) was purchased from Johnson Matthey (Switzerland). Water for synthesis was taken from a reverse osmosis system and distilled twice before use. For HPLC measurements Milli-Q water (18.2 MΩ•cm, Merck Milli-Q Advantage, Darmstadt, Germany) was used. Other chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, Merck, Acros, Fluka and Fisher Scientific).
Cisplatin 1 (1) and oxaliplatin 2 (2) were prepared according to literature procedures.
Thereafter, the complexes were oxidized with hydrogen peroxide (50%) using either methanol 3 or acetic acid 4 as a solvent to yield the unsymmetrically oxidized platinum(IV) precursors 3-6. The maleimide-and succinimide-functionalized ligands were prepared as recently published. 5 Electrospray ionization (ESI) mass spectra were recorded on a Bruker amaZon SL ion trap mass spectrometer in positive and/or negative mode by direct infusion.
High resolution mass spectra were measured on a Bruker maXis™ UHR ESI time of flight mass spectrometer. All mass spectra were recorded at the Mass Spectrometry Centre of the University of Vienna. One-and two-dimensional 1 H-, 13 C-, 15 N-and 195 Pt-NMR spectra were recorded on a Bruker Avance III 500 MHz spectrometer at 500. 10 ( 1 H), 127.75 ( 13 C), 50.68 ( 15 N), and 107.51 ( 195 Pt) MHz at 298 K. For 1 H-and 13 C-NMR spectra the solvent residual peak was taken as internal reference, whereas 195 Pt-shifts were referenced relative to external K 2 PtCl 4 and 15 N-shifts relative to external NH 4 Cl. Elemental analysis measurements were performed on a Perkin Elmer 2400 CHN Elemental Analyzer at the Microanalytical Laboratory of the University of Vienna.
Synthesis

General procedure for the synthesis of compounds 7-14:
The unsymmetrically, oxidized platinum(IV) compound (3) (4) (5) (6) and the corresponding isocyanate were transferred into a Schlenk flask and set under argon atmosphere. After the addition of dry DMF, the suspension was stirred overnight. A remaining precipitate was filtered, before the DMF was removed under reduced pressure. The residue were taken up as a suspension in methanol and fully precipitated by addition of diethylether. After a few hours in the fridge the crude product was filtered off, washed with diethylether and dried under reduced pressure. The solid was taken up in water and filtered before it was purified by preparative RP-HPLC. Collected product fractions were concentrated, to remove methanol, thereafter lyophilized and dried under reduced pressure.
Purification of compounds 7-14 by preparative RP-HPLC:
All compounds were purified by preparative RP-HPLC using a Waters XBridge C18 column on an Agilent 1200 Series system. Milli-Q water, containing 0.1% formic acid, and methanol were used as eluents. Single crystal X-ray crystallography
The X-ray intensity data were measured on a Bruker D8-Venture equipped with a multilayer monochromator, a Cu-K α INCOATEC micro focus sealed tube and Kryoflex II cooling device.
The results were uploaded to the CCDC (codes see Table S1 ). The structures were solved by direct methods and refined by full-matrix least-squares techniques. Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were inserted in calculated positions and refined with a riding model respectively as rotating systems. The following software was used: Frame integration, Bruker SAINT software package 7 using a narrow-frame algorithm, Absorption correction, SADABS, 8 structure solution, SHELXS-97, 9 refinement, SHELXL-2013, 9 SHELXLE, 10 molecular diagrams and OLEX2. 11 Experimental data can be found in Table S1 . Crystal data, data collection parameters, and structure refinement details are given in Table S2-S3 and Table S5 -S6. Molecular Structures in "Ortep View" are depicted in Figure S1 and Figure S2 . Figure S1 : Asymmetric unit of 7 drawn at 50% displacement ellipsoids. 
RP-HPLC stability and binding studies
To determine the stability, especially of the maleimide-function, 0.5 mM solutions of the complexes were prepared in triple distilled water and measured repeatedly over several hours. For determination of the binding rate towards human serum albumin (HSA), freshly prepared 1 mM aqueous solutions of a compound and HSA were mixed 1:1 and also measured repeatedly over several hours. All studies were carried out using a reversed-phase Waters XBridge C18 column on a Dionex Summit System. Milli-Q water, containing 0.1% formic acid, and methanol were used as eluents and a standard gradient from 5-95% methanol in 20 minutes was chosen. The autosampler, where the samples were incubated, was temperature controlled at 20°C and the column at 25°C. The loss of the complexes was monitored via UV-VIS detector at 225 nm and evaluated by the decrease of the compound peak area.
SEC-ICP-MS studies
A reagent I grade water (>10 MΩ cm -1 resistance according to ISO 3696 water specifications) purification system (Ultra Clear basic Reinstwassersystem, SG Wasseraufbereitung und Regenerierstation GmbH, Barsbüttel, Germany) was used. Ammonium acetate (≥99%), glutathione disulfide (≥98%), human serum albumin (96-99%), myoglobine from equine skeletal muscle (95-100%) and homocysteine (≥98%) were purchased from Sigma Aldrich, St.
Louis, MO, USA. The platinum standard (1002±6 µg/mL) was purchased from Inorganic Ventures, Christiansburg, Virginia, USA. Methionine (≥99%) and glutathione (≥99%) were purchased from Merck (Darmstadt, Germany). Fetal Calf Serum (FCS) was kindly provided by Prof. Walter Berger from the Institute of Cancer Research, University of Vienna, Austria.
SEC-ICP-MS stability and FCS binding studies
For sample preparation compounds 7-14 were incubated separately in FCS. For this purpose they were dissolved in water and finally diluted 1:10 in FCS to obtain a final concentration of 100 µM. The samples were then stored in the autosampler at 37°C for 21 h and analyzed every 2:20 h.
For ICP-MS measurements an ICP-QMS ELAN DRC II PerkinElmer (Ontario, Canada) equipped
with a dynamic reaction cell was used. Oxygen (purity 4.5, Linde Gas GmbH, Vienna, Austria) was used as reaction gas. The ICP-MS operation parameters are given in Table S8 . The analysis was carried out in isocratic mode and the flow was split 1:1 after the column since the concentration (100 µM) for the incubation carried out in the autosampler was too high and not suitable for the ICP-MS detector. The chromatographic conditions are shown in Table S9 .
A flow injection analysis (FI) was carried out to determine the real concentration of the platinum drugs in FCS and the column recovery. The column recovery was determined at time 0 h of incubation. The results are given in Table S10 . A protein/amino acid mix was prepared to assess the separation performance of the applied SEC-HPLC setup. The mixture contained HSA, myoglobin, GSSG, and methionine. It has to be mentioned that HSA is forming dimers over time. However, the separation of the monomer and the dimer of HSA cannot be resolved with this chromatographic column. 
SEC-ICP-MS measurements of in vivo serum samples
The ICP-QMS iCAP Thermo Scientific (Bremen, Germany) was used. Oxygen (purity 4.5, Linde
Gas GmbH, Vienna, Austria) was used as reaction gas. The ICP-MS operation parameters are given in Table S12 . As HPLC system a Thermo Scientific Transcend HPLC system (San Jose, CA, USA) was coupled to the ICP-QMS iCAP Thermo Scientific. Qtegra Intelligent Scientific Data Solution (version 2.4.1800.33) was employed for the data treatment. HPLC chromatographic conditions are given in Table S13 . A flow injection analysis (FI) was carried out to determine the real concentration of the platinum drugs in FCS and the column recovery. The results are given in Table S14 . 
DLS measurements
The samples were prepared by incubating 100 µM HSA with either 5 eq. of the oxaliplatinbased maleimide compound 12 or 5 eq. of the cisplatin-based maleimide compound 8 in 50 mM phosphate buffer (pH=7.4) for 6 h on a stirring table. As a reference, a HSA sample in 50 mM phosphate buffer (pH=7.4) without addition of a platinum compound was also put on a stirring table for 6 h. Prior to the measurements, the samples were diluted 1/9 (v/v) with 50 mM phosphate buffer (pH=7.4). The DLS spectra were recorded on a Malvern ZetaSizer Nano ZS (Malvern Instruments Ltd., Malvern, UK) equipped with a 4 mW He-Ne, 632.8 nm laser beam at 25 °C and at a scattering angle of 173 °.
In vivo studies
Cell culture
The murine (Balb/c) colon cancer cell model CT-26 (purchased from American Type Culture Collection, Manassas, VA, USA) was used. Cells were grown in DMEM/F12 (1:1) supplemented with 10% FCS. All cell culture media and reagents were purchased from Sigma-Aldrich Austria.
Animals
Six-to eight-week-old Balb/c mice (~20-25 g) were purchased from Harlan Laboratories (San Pietro al Natisone, Italy). The animals were kept in a pathogen-free environment and every 
CT-26 experiments
CT-26 cells (5x10 5 in serum-free medium) were injected subcutaneously into the right flank of Balb/c mice (gender is indicated in the respective figure). Animals were treated with the indicated oxaliplatin-releasing drugs at concentrations equimolar to 9 mg/kg oxaliplatin (i.v.;
12 was dissolved in 0.9% NaCl solution, 11 in 10% propylene glycol/0.9% NaCl, and oxaliplatin in 5% glucose solution according to the clinical protocol) twice a week (Mondays and Thursdays). In case of cisplatin-releasing prodrugs, a dose equimolar to 3 mg/kg cisplatin was applied twice a week. For all experiments four animals per treatment group were used.
Animals were controlled for distress development every day and tumor size was assessed regularly by caliper measurement. Tumor volume was calculated using the formula: (length × width 2 ). The experiments with oxaliplatin, 11 and 12 in male mice were performed twice with two different endpoints: 1) overall survival and 2) collection of organ and tumor material 24 h after the last day of treatment. In the second experiments, tumors were formalin-fixed and paraffin-embedded. The experiment with oxaliplatin and 12 in female mice was performed only with the endpoint overall survival. For cisplatin and 8, the experiment with endpoint of organ and tumor collection 24 h after the last day of treatment was performed. For histological evaluation, tumor tissues were sliced and haematoxylin/eosin stained by routine procedures.
Organ distribution experiments
CT-26 cells (5x10 5 in serum-free medium) were injected subcutaneously into the right flank of Balb/c mice. When tumors reached a size of about 500 mm 3 , animals were treated once with the platinum compounds as described above. After 24 h, animals were anaesthetized and sacrificed by heart puncture. Serum was isolated from the collected blood samples by centrifugation at 3000 rpm for 10 min for two times and stored together with the collected tissue samples at -20 °C.
Statistics
Results were analyzed and illustrated and statistical analyses performed (as indicated) with
GraphPad Prism (GraphPad Software version 5,San Diego, CA).
Determination of the platinum concentration in mice tissues by ICP-MS
Digestion of tissue and blood samples (approx. 20 mg or 50 µL gravimetrically) were performed with 2 ml of nitric acid (~30%) using a microwave system (Discover SP Table S15 . The instrument was tuned on daily basis to achieve maximum sensitivity. Reduction experiments 1 mM solutions of the succinimide derivatives 9-10 and 13-14 in 100 mM phosphate buffer Table S16 -S18. At day 12 after first treatment, animals were sacrificed and tumor tissues collected, formalin-fixed, paraffin-embedded and H/E-stained. The fractions of apoptotic and mitotic cells were evaluated by counting (4 pictures per sample, at least 300 cells per picture were counted). Each experimental group contained four animals (the respective tumor growth is shown in Figure 4A ). a n=3 because of one complete remission. The statistical significance was calculated by One-Way Anova and is indicated with asterisks (* P < 0.05; ** P < 0.01; *** P < 0.001). 
